In scope: WPP’s health assets, Inizio, Omnicom Health, Real Chemistry, OPEN Health, Syneos Health and Envision. Health communications work only. Below is the 2026 record so far.

Products and platforms

14 July — Real Chemistry launches ANATOMI, an AI ecosystem covering the commercialisation lifecycle, including a publications workflow.

28 July — Inizio Engage launches Connected Insights, applying AI to medical information interactions across 20+ languages.

January (approx) — Omnicom unveils the next generation of Omni at group level, integrating Interpublic assets, Acxiom identity data and autonomous agents.

Predating this year: Inizio Medical launched iON AI in March 2025; Envision launched 4Sight in July 2024.

Partnerships

14 May — Syneos expands its AI partnerships to include Sageforce AI-powered field teams — AI MSLs, field reimbursement managers, nurse navigators, virtual sales representatives — and causaLens causal-AI agents across commercial operations.

Structure and roles

26 February — WPP ends its holding company model, folding Ogilvy, VML and AKQA into four divisions, targeting £500m in savings and an AI-enabled operating structure.

Mid-2026 — Omnicom Health Medical Communications debuts as a roll-up of ten medcomms agencies: estimated $360m revenue, 1,450 staff.

August 2024 — Syneos appointed a dedicated AI innovation lead in its US PR practice.

Published positions

21 January — Envision’s VP of AI publishes ten AI game-changers for 2026: generative content, automated literature review, congress intelligence, MLR automation, synthetic KOLs.

30 January / 10 April — OPEN Health publishes on AI-accelerated RWE, then assesses AI readiness across HEOR: strongest in structured, repeatable tasks; weakest in judgement-driven work.

6 April — Omnicom Health publishes eight signals on the future of health at SXSW.

21 May — Ogilvy Health goes on record about its AI adoption pace and its Ria tool.

13 July — Envision publishes a whitepaper on AI-simulated advisory boards.

One observation, offered as no more than that: the tasks these products target are consistent across agencies — drafting, summarising, reference checking, evidence synthesis.

What the record does not contain: any published evidence of traction. No renewals, client wins or revenue attributed to any of these tools. Announcements are not adoption, and I won’t treat them as such. Nor does a launch date tell you whether the thing works, or whether the acquisition behind it went well.

Corrections and additions welcome — particularly from anyone who has used these tools rather than read about them. Reply and tell me.

— Ned

Follow the conversation: #IrreplaceablesHealth